BCRX Q1 2017 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+95.8% YoY

Gross Profit

$9M96.9% margin

Operating Income

-$11M-113.2% margin

Net Income

-$14M-150.7% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+5.1%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$130M

Total Liabilities

$91M

Stockholders' Equity

$39M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$5M	+95.8%
Gross Profit	$9M	$5M	+92.8%
Operating Income	-$11M	-$19M	+43.9%
Net Income	-$14M	-$23M	+37.7%